COCRYSTAL PHARMA, INC. Net Fee Amt
COCRYSTAL PHARMA, INC. (COCP) had Net Fee Amt of $671.12 as of 2026-04-23, per its S-3 filed 2026-04-23.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-23
- 2026-04-23: Net Fee Amt $671.12.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-23 | $671.12 S-3 · filed 2026-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |